

Boehringer Ingelheim
Pharmaceuticals Inc.

U.S. Nuclear Regulatory Commission
Region 1
Division of Nuclear Materials and Safety
475 Allendale Road
King of Prussia, PA 19406-1415

H-Ø

25 May, 2005

Re: Mail Control No. 137007
Boehringer Ingelheim Pharmaceuticals, Inc.
Request for Amendment to License 06-19183-01

To Whom It May Concern,

03017101


This letter supplements the letter of May 3, 2005 (Mail Control No 137007) from Ms. Patricia Lopez, Radiation Safety Officer for Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). In that letter she requests, on BIPI's behalf, to remove Ni-63 from the source material inventory for our License No. 06-19183-01.

Karl D. Hargrave, Ph.D.
Telephone 203-798-5136
Telefax 203-791-6468
E-Mail khargrav@rdg.boehringer-
ingelheim.com

900 Ridgebury Rd/P.O. Box 368
Ridgefield, CT 06877-0368
Telephone (203) 798-9988

Patricia Lopez is an external consultant and thus it has been BIPI's desire to train and have an in-house employee as RSO. To that end, I wish to inform the NRC that Dr. Michael Cerreta, a BIPI employee, has been undergoing the training necessary to qualify as RSO. While his credentials have not yet been reviewed by BIPI's Radiation Safety Committee (RSC) or the Institutional Officer (IO), I would suggest that the license amendment requested in the May 3 letter referenced above be held by the NRC until Dr. Cerreta has met the requirements of 10 CFR 35.50 and has been approved as RSO by BIPI's RSC and IO, and by the NRC. In this way a single amended license may incorporate both requested changes.

Sincerely,



Karl D. Hargrave, Ph.D.
Chairman, Radiation Safety Committee
KDH/sn

cc: Mr. Art Slesinger, Corporate Director
Environmental & Safety Affairs

05 MAY 27 P1:54

RECEIVED
REGION 1

137007

NMSS/RGNI MATERIALS-002